Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb

  Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement
                          with Bristol-Myers Squibb

PR Newswire

SEATTLE, May 9, 2013

SEATTLE, May 9, 2013 /PRNewswire/ --Adaptive Biotechnologies announced today
that it has entered into a collaboration agreement with Bristol-Myers Squibb
for the discovery of immunological biomarkers in oncology.

(Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO)

Under the collaboration, Adaptive will use its proprietary immune profiling
assay, immunoSEQ, to identify potential biomarkers that may inform about drug
response. The immunoSEQ assay uses high throughput next-generation sequencing
to characterize the repertoire of T and B cell receptors. Application of this
technology is being explored in cells of cancer patients, to assess the impact
of treatments on the immune system and evaluated as a tool to identify patient
populations who might be more likely to respond to targeted therapies based on
their immune status.

"We are delighted to collaborate with Bristol-Myers Squibb to help uncover
immunological biomarkers of response to cancer agents," said Chad Robins, CEO
and Founder of Adaptive Biotechnologies. "Collaborating with Bristol-Myers
Squibb is a real win for companies like ours that are committed to deepening
the understanding of the interaction between the host immune system and the
cancer cells themselves."

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com),
headquartered in Seattle, WA, is pioneering the field of genomic immunology.
The company's core competency is developing next generation sequencing assays
that characterize the adaptive immune system, serving as a platform technology
to the research and clinical communities as well as the biopharmaceutical
industry. Adaptive operates a state-of-the-art high throughput centralized
laboratory in Seattle that is CLIA certified and will be accepting clinical
samples in 2013. Its flagship commercial product, immunoSEQ
(http://www.immunoSEQ.com), uses a proprietary immune profiling assay to
analyze T cells and B cells – critical components of the adaptive immune
system's defense against disease – with unprecedented depth and specificity.
In 2013, the company will introduce clonoSEQ (http://www.clonoseq.com), a
clinical assay to measure and monitor minimal residual disease (MRD) in a
range of blood-based cancers that is significantly more sensitive than today's
most common tests. All of Adaptive Biotechnologies' assays are coupled with a
cloud-computing infrastructure that simplifies the interpretation of massive
quantities of data in a user-friendly interface.

SOURCE Adaptive Biotechnologies Corporation

Website: http://www.immunoseq.com
Contact: Chad Robins, CEO & President, crobins@adaptivebiotech.com